QD502

QD502 is a **preclinical, orally bioavailable quinazoline-based small molecule** being developed by **KOR Life Sciences** for **pancreatic ductal adenocarcinoma** and **glioblastoma**. The program is described as a **pro-oxidant / reactive oxygen species modulating antineoplastic agent** intended to dysregulate tumor redox balance and induce anti-tumor effects through oxidant regulation. Publicly available company pipeline information indicates that QD502 is part of a University of Michigan-associated collaboration and is in **preclinical / IND-enabling development**, with no clinical trials identified from the provided context.